Price
No data yet.
Social Signal Score
Analyst Ratings
23 analystsRevenue
$27.49M+755.26%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel Faga
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 104
- Beta
- 0.41
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 3.14
Financials
Revenue
$27.49M+755.3%Net Income
$183.88MEBITDA
$66.96MFree Cash Flow
$-26.62MEPS (diluted)
$5.11Shares Outstanding (diluted)
35.98M+1264.8%Operating Expenses
$18.75MCash & Debt
$164.14MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $234.60M | $-13.23M | $-0.46 |
| 2024 | $91.28M | $-145.23M | $-5.12 |
| 2023 | $17.16M | $-163.62M | $-6.08 |
| 2022 | $10.29M | $-128.72M | $-4.57 |
| 2021 | $63.17M | $-57.80M | $-2.11 |
| 2020 | $75.00M | $-19.93M | $-0.73 |
| 2019 | $8.00M | $-97.34M | $-3.60 |
| 2018 | $5.00M | $-61.66M | $-2.50 |
| 2017 | $10.00M | $-30.07M | $-1.52 |
| 2016 | $16.68M | $-4.26M | $-0.23 |
| 2015 | $17.57M | $-5.41M | $-0.38 |
| 2014 | $15.84M | $232.0K | $0.24 |
| 2013 | $5.48M | $-5.54M | $-2.28 |
Valuation
ANABhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
90Social Signal Score
Mentions (2)
- Newszacks.com·1d ago·Negative
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $1.34 per share a year ago.
View source ↗ - Newsglobenewswire.com·1d ago·Neutral
Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update.
View source ↗
Earnings
Tue, Nov 3(in 6 weeks)
Consensus estimate $-0.06 per share
Typical surprise +53.5% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Sep 21$5.11 vs $-0.47beat
- Tue, May 12$-1.84 vs $-0.32miss
- Tue, Mar 3$1.58 vs $0.89beat
- Tue, Nov 4$0.52 vs $-1.06beat
- Thu, Aug 7$-1.34 vs $-1.50beat
- Mon, May 5$-1.28 vs $-1.30beat
Estimates and results for ANAB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ANAB officers and directors.
- Bought
- —
- Sold
- $3.2m
0 trades
15 trades
- Schmid John P.sold
- Schmid John P.sold
- Schmid John P.sold
- Faga Danielsold
- Faga Danielsold
- Faga Danielsold
- Faga Danielsold
- Faga Danielsold
85 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ANAB.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.